IKZF1

InnoCare Releases 2023 Results and Business Highlights

Retrieved on: 
Thursday, March 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, QD, Tafasitamab, Patient, B-cell lymphoma, NDA, SLE, POC, IND, Clinical trial, Bone marrow, IKZF1, Phase, Therapy, IGA, MCD, Dexamethasone, MCL, Neuromyelitis optica spectrum disorder, IKZF3, AML, NMOSD, Outline of health sciences, DLT, Cancer, Autoimmune disease, Safety, TYK2, HSA, NRDL, BLA, Follicular lymphoma, Food, GC, Development, Multiple sclerosis, PD, CRBN, Public, Gordon Ramsay's Bank Balance, Multiple myeloma, ITP, BCL2, Leukemia, Cmax, Gadolinium, HKEX, SRI, AAD, Proteinuria, DLBCL, Glucocorticoid, IVIG, Loss, European Hematology Association, American Academy, EHA, Lenalidomide, NHL, Non-Hodgkin lymphoma, CCR8, US FDA, BTK, NRS, Pharmaceutical industry

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.
  • In 2023, InnoCare has continued to advance its robust pipeline across various clinical stages, continuously unleashing the power of innovation to meet unmet medical needs.
  • In June 2023, the ITP Phase II result was orally presented at the European Hematology Association (EHA) 2023 Hybrid Congress.
  • InnoCare was approved by the Hong Kong Stock Exchange to remove "B" from the stock code from May 12, 2023.

Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases

Retrieved on: 
Monday, January 8, 2024
Conference, Drug discovery, Lymphoma, Lymphoid leukemia, IND, DLBCL, Antibody, Leukemia, IKZF3, Inflammation, Mantle cell lymphoma, SAN, Society, IKZF1, Therapy, Cancer, Clinical trial, Paclitaxel, Rheumatoid arthritis, Chronic lymphocytic leukemia, B-cell lymphoma, ASH, CLL, NHL, Business development, BTK, Patient, MCL, Pharmaceutical industry

SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today outlined key objectives and anticipated milestones for 2024 and provided an overview of recent progress in a presentation at the 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • A webcast of Nurix’s ASH presentation is available in the Investors section of the Nurix website under Events and Presentations .
  • Nurix is evaluating daily oral dosing of NX-5948 in a Phase 1a/1b clinical trial in patients with relapsed or refractory B-cell malignancies.
  • Nurix plans to present and publish preclinical work on its wholly owned programs throughout 2024 at appropriate scientific and medical meetings.
  • Research milestones: Nurix expects to achieve multiple research collaboration milestones throughout 2024 from its existing collaborations with Gilead, Sanofi, and Pfizer.

Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Monday, December 11, 2023
Drug resistance, Atrial fibrillation, Exposition, Lymphoid leukemia, Șaeș, DLBCL, PRS, Hypertension, Anemia, IKZF3, PCNS, Mantle cell lymphoma, Neutropenia, City, SAN, Society, Therapy, Follicular lymphoma, IKZF1, Infrared spectroscopy correlation table, Bone marrow, ASH, CLL, NHL, CNS, BTK, Patient, Safety, Lymphoma, Immunotherapy, KOL, MCL, Pharmaceutical industry

SAN FRANCISCO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today presented positive clinical data from its orally available degraders of BTK, NX-5948 and NX-2127, which are being evaluated in separate Phase 1a/1b clinical trials in patients with relapsed or refractory (r/r) B-cell malignancies, including CLL, mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), primary CNS lymphoma (PCNS), and Waldenström’s macroglobulinemia (WM). These data were presented in two posters at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, which is being held in San Diego, California.

Key Points: 
  • These data were presented in two posters at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, which is being held in San Diego, California.
  • BTK degraders represent a novel next generation therapy for these patients,” said Alexey Danilov, M.D., Ph.D.
  • Professor and Co-Director, Toni Stephenson Lymphoma Center, City of Hope National Medical Center and an investigator on both studies.
  • “CLL patients whose disease progresses on or after treatment with BTK inhibitors, most often due to the development of resistance, have no effective treatment options.

Bionano Announces Peer-Reviewed Publication on the Utility of Combining OGM and WES for Evaluation of Pediatric Leukemia

Retrieved on: 
Wednesday, September 6, 2023
HD, ETV6, FISH, Genomics, Fluorescence, STAG2, KT, NGS, SVS, BTG1, IKZF1, Karyotype, BCP, PDS5B, SNP, SAN, MANBA, German Cancer Research Center, In situ hybridization, TBL1XR1, WES, Leukemia, SNV calling from NGS data, OGM, Bone marrow, Medical imaging

SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication from researchers at the German Cancer Consortium (DKTK) showing the utility of optical genome mapping (OGM) and whole-exome sequencing (WES) in better understanding the mutational landscape of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL).

Key Points: 
  • SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication from researchers at the German Cancer Consortium (DKTK) showing the utility of optical genome mapping (OGM) and whole-exome sequencing (WES) in better understanding the mutational landscape of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
  • Researchers compared the analysis of 60 pediatric BCP-ALL samples using traditional cytogenetic methods against OGM and WES, finding that OGM and WES may provide novel insights into disease development and progression.
  • It also shows the potential of combining OGM with WES to identify double hits, which are highly significant.
  • It’s noteworthy that long-read sequencing confirmed the fusions detected by OGM once OGM revealed the regions in which to look for them, highlighting the possibility that OGM can be a primary tool used alongside short-read next-generation sequencing (NGS).

Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities

Retrieved on: 
Monday, January 9, 2023
IND, Luman Hamlin Weller, Non-Hodgkin lymphoma, Science, MHRA, Lymphoma, Therapy, Gilead Sciences, IKZF1, BTK, Biotechnology, Standby Equity Distribution Agreement, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Safety, CLL, FDA, IKZF3, Immunotherapy, Head, ASH, Conference, Innovation, Lymphatic system, Food, Health care, Chronic lymphocytic leukemia, Society for Immunotherapy of Cancer, Patient, Cancer, SAN, Clinical trial, Sale, SITC, Annual general meeting, Pharmaceutical industry, Vaccine, Sanofi

SAN FRANCISCO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today outlined key objectives and anticipated milestones for 2023 and provided an overview of recent progress in a presentation at the 41st Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • Nurix also anticipates defining a regulatory strategy for NX-2127 in H2 2023 based on emerging clinical data and feedback from the U.S. Food and Drug Administration (FDA).
  • In addition, Nurix expects to define a dose for Phase 1b cohort expansion in H2 2023.
  • New drug candidate: Nurix expects to select a new targeted protein degrader development candidate in 2023.
  • Research milestones: Nurix expects to achieve substantial research collaboration milestones throughout 2023 from its existing collaborations with Gilead Sciences and Sanofi.

Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Monday, December 12, 2022
IKZF3, Follicular lymphoma, BCL2, Chronic lymphocytic leukemia, Phase, Enzyme, IKZF1, ClinicalTrials.gov, Protein, Clinical trial, SAN, MTD, Mantle cell lymphoma, SKI, Lymphocytosis, KOL, Lymphoid leukemia, Safety, CLL, Cancer, Memorial Sloan Kettering Cancer Center, Pharmacokinetics, Exposition, MSCE, ASH, B-cell lymphoma, ORR, BTK, Non-Hodgkin lymphoma, Waldenström's macroglobulinemia, MCL, Society, Therapy, DLBCL, Lymphatic system, Index (publishing), COVID-19, Risk, Patient, SLL, Pharmaceutical industry

SAN FRANCISCO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today presented additional positive clinical data from its Phase 1 clinical trial of NX-2127 in two oral sessions by Anthony Mato, M.D., MSCE, former director of the Chronic Lymphocytic (CLL) Program at Memorial Sloan Kettering Cancer Center, and Omar Abdel-Wahab, M.D., Chair of Sloan Kettering Institute (SKI) Molecular Pharmacology Program at Memorial Sloan Kettering Cancer Center. NX-2127 is a once daily, oral, investigational new drug that combines BTK degradation with immunomodulatory activity. The podium presentations took place at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition which is being held in New Orleans, Louisiana.

Key Points: 
  • The podium presentations took place at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition which is being held in New Orleans, Louisiana.
  • Approximately 78% of this group had previously received both BTK and BCL2 inhibitors and 35% had been treated with the non-covalent BTK inhibitor pirtobrutinib.
  • Of the CLL patients, 48% had one or more identified BTK resistance mutations prior to treatment with NX-2127.
  • These findings translated into clinically meaningful BTK degradation in the Phase clinical 1 trial and clinical activity independent of baseline BTK mutations.

Nurix Therapeutics Announces Webcast to Review Data from its Phase 1 Clinical Trial of BTK Degrader, NX-2127, Presented at the 64th American Society of Hematology Annual Meeting

Retrieved on: 
Wednesday, December 7, 2022
Chronic lymphocytic leukemia, IKZF3, IKZF1, Enzyme, Protein, Clinical trial, SAN, SKI, Webcast, CLL, Cancer, Memorial Sloan Kettering Cancer Center, Laboratory, MSCE, BTK, Research, Therapy, Lymphatic system, Patient, Pharmaceutical industry

The live webcast, as well as a replay, will be available in the Investors section of the Nurix website under Events and Presentations .

Key Points: 
  • The live webcast, as well as a replay, will be available in the Investors section of the Nurix website under Events and Presentations .
  • NX-2127 is a novel bifunctional molecule that degrades Bruton’s tyrosine kinase (BTK) and cereblon neosubstrates Ikaros (IKZF1) and Aiolos (IKZF3).
  • NX-2127 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies.
  • Additional information on the ongoing clinical trial can be accessed at www.clinicaltrials.gov ( NCT04830137 ).

Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Patient, Lymphoid neoplasms with plasmablastic differentiation, Private Securities Litigation Reform Act, Society, Biology, Lymphoma, FDA, IKZF1, University, Annual report, U.S. Securities and Exchange Commission, Clinical trial, MD Anderson Cancer Center, Ewing's sarcoma, Research institute, SEC, Department, 2021 Essex County Council election, Food, GLOBE, ASH, SUSAR, CMML, Lenalidomide, Cancer, Drug development, Myelodysplastic syndrome, Sarcoma, Salinicola salarius, Efficiency, MDS, Research, Drug resistance, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Review, Pharmacology, Life, LSD1, Exposition, Food and Drug Administration, Investor, Chronic myelomonocytic leukemia, Effectiveness, Trial of the century, Hematological Cancer Research Investment and Education Act, NASDAQ, MD, Pharmaceutical industry, Vaccine, IND, Azacitidine

One abstract highlights preclinical work by Salarius with SP-3164 and the other highlights clinical work by collaborators at the University of Texas MD Anderson Cancer Center with seclidemstat.

Key Points: 
  • One abstract highlights preclinical work by Salarius with SP-3164 and the other highlights clinical work by collaborators at the University of Texas MD Anderson Cancer Center with seclidemstat.
  • SP-3164 showed increased IKZF1 degradation efficiency compared with other molecular glues and significant anti-cancer activity as a monotherapy in an in vivo lymphoma mouse xenograft model.
  • Salarius Pharmaceuticals, Inc.is a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options.
  • This announcement and the referenced presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Chronic lymphocytic leukemia, Patient, Memorial Sloan Kettering Cancer Center, Protein, BTK, Lymphatic system, Private Securities Litigation Reform Act, SAN, Society, GLOBE, IKZF3, Acute leukemia, IKZF1, Uncertainty, Relapse, Therapy, COVID-19, Nasdaq, Intention, Clinical trial, Forward-looking statement, Enzyme, Goal, SEC, Cancer, Pharmaceutical industry

NX-2127 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies.

Key Points: 
  • NX-2127 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies.
  • Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct.
  • The statements in this press release speak only as of the date of this press release, even if subsequently made available by Nurix on its website or otherwise.
  • Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.

Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit

Retrieved on: 
Wednesday, October 26, 2022
ASH, IKZF3, SEC, Clinical trial, BTK, Private Securities Litigation Reform Act, Nasdaq, Cancer, Forward-looking statement, Goal, DLBCL, Keynote, Prognosis, Risk, Lymphoma, CLL, Lymphatic system, CAR, IKZF1, Patient, Protein, Poster, B-cell lymphoma, COVID-19, GCB, Enzyme, GLOBE, Therapy, SAN, Head, Chronic lymphocytic leukemia, Intention, NHL, Medicine, ABC, Pharmaceutical industry, Medical imaging

SAN FRANCISCO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced the presentation of new preliminary clinical data comprised of a case study of a patient with aggressive non-germinal center B-cell (non-GCB) diffuse large B cell lymphoma (DLBCL). The patient receiving 300 mg once per day of NX-2127 experienced a complete response at 8 weeks which was confirmed at 16 weeks and remains ongoing. These data were presented by Arthur T. Sands, M.D. Ph.D., Nurix’s president and chief executive officer, in a Keynote Plenary session of the 5th Annual TPD Summit which is being held from October 25 – 28, 2022 in Boston, MA.

Key Points: 
  • The patient receiving 300 mg once per day of NX-2127 experienced a complete response at 8 weeks which was confirmed at 16 weeks and remains ongoing.
  • We look forward to further exploring the activity of NX-2127 in the ongoing study.
  • The patient presented is enrolled in the Phase 1a dose escalation stage of an ongoing clinical trial to evaluate the activity of NX-2127 in non-Hodgkins lymphomas.
  • The patient was treated at the 300 mg dose and remains on study with a complete response first achieved at the 8-week assessment and confirmed at week 16.